Please login to the form below

Not currently logged in
Email:
Password:

Ablynx

This page shows the latest Ablynx news and features for those working in and with pharma, biotech and healthcare.

Sanofi appoints ex-Roche Reed as new R&D head

Sanofi appoints ex-Roche Reed as new R&D head

The Paris-headquartered firm also secured two major acquisitions in January, buying US haemophilia specialist Bioverativ for $11.6 billion and Belgium’s next-generation biologics firm Ablynx for 3.9 ... Sanofi currently has just one drug pending FDA

Latest news

More from news
Approximately 7 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Ablynx submitted its MAA to the EMA for approval of caplacizumab in February last year and, according to Reuters, Ablynx has forecast peak caplacizumab sales of 1.2bn. ... Acquisition company. 7, 000. Ablynx/Sanofi. Nanobody platform product pipeline;

  • Deal Watch November 2015 Deal Watch November 2015

    410. Ablynx. Novo Nordisk. Discovery collaboration, licence. Multi specific Nanobody drug candidates in undisclosed TA with option to expand to second Nanobody programme.

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    25, 000. Ablynx / Merck &Co. Collaboration. Nanobody candidates to target “ immune checkpoint modulators”.

  • Pharma deals during February 2014 Pharma deals during February 2014

    It is has been a busy month for Merck &Co. Belgian-based Ablynx has signed a second exclusive collaboration and licensing deal with the company to focus on the discovery and ... Under the terms of the agreement, Ablynx will receive an upfront payment of

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    25. †† Ablynx / Eddingpharm. Licence. Anti-RANKL Nanobody, ALX-0141 for osteoporosis and bone metastases (preclinical).

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma

  • Apitope strengthens its board with new director Apitope strengthens its board with new director

    He has also served on several boards including Ablynx, Evotec and Acambis.

  • Ablynx reshuffles its board again Ablynx reshuffles its board again

    Ablynx reshuffles its board again. Dr Bo Jesper Hansen resigns from the Belgium biotech's board. ... After one month as Ablynx’s chairman of the board of directors, Dr Bo Jesper Hansen (pictured) has resigned from the position due to personal reasons.

  • Robert Freisen joins Ablynx Robert Freisen joins Ablynx

    Robert Freisen joins Ablynx. He will take the role of chief scientific officer, effective March 1. ... He said: “I have long admired Ablynx and am excited to join the company at such an important time.

  • Novo Nordisk target Ablynx reshuffles its board Novo Nordisk target Ablynx reshuffles its board

    Novo Nordisk target Ablynx reshuffles its board. Dr Bo Jesper Hensen has been elected as biopharma’s new chairman. ... Heading up the board is Ablynx ’s non-executive director Dr Bo Jesper Hensen (pictured), who was unanimously elected as its new

More from appointments
Approximately 5 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics